Phase II Study of Grass Pollen Allergy Vaccine BM32

Summary

The study will evaluate the efficacy and safety of BM32 in grass pollen allergic subjects. It will test the hypothesis that either of two doses of BM32 will lead to a sustained relief off allergy symptoms over a two year study period.

Timeline

Start

2012-03

Primary completion

2014-12

Completion

2015-03

Drugs

Indications